Concepedia

Mirjam Hau

MH

6

Publications

151

Citations

6

H-Index

2016

Active since

Affiliations

University of Freiburg(Current)

University Medical Center Freiburg

University of Dundee

Deutschen Konsortium für Translationale Krebsforschung

German Cancer Research Center

Mirjam Hau is an author at University of Freiburg specializing in pharmacotherapy, drug development, and drug discovery.

Top concepts

MedicinePharmacologyDrug DiscoveryPharmacotherapyDrug DevelopmentNatural SciencesCell BiologyTumor BiologyCancer BiologyCancer Therapy

Publications per year

2016–2020

6

Publications

6

Structure-activity studies on N -Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation

Johannes Schulz‐Fincke, Mirjam Hau, Jessica Barth et al. · European Journal of Medicinal Chemistry · 2017 · 36 citations · Full text

Tranylcypromine Derivatives, Drug Target, Medicine +11

Beyond the BET Family: Targeting CBP/p300 with 4‐Acyl Pyrroles

Martin Hügle, Xavier Lucas, Dmytro Ostrovskyi et al. · Angewandte Chemie International Edition · 2017 · 34 citations · Full text

Drug Target, Chemoprevention Strategy, Pharmacotherapy +21

Nitroreductase‐Mediated Release of Inhibitors of Lysine‐Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells

Eva‐Maria Herrlinger, Mirjam Hau, Desiree Melanie Redhaber et al. · ChemBioChem · 2020 · 22 citations · Full text

Beyond the BET Family: Targeting CBP/p300 with 4‐Acyl Pyrroles

Martin Hügle, Xavier Lucas, Dmytro Ostrovskyi et al. · Angewandte Chemie · 2017 · 21 citations

4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines

Martin Hügle, Pierre Regenass, Robin Warstat et al. · Journal of Medicinal Chemistry · 2020 · 20 citations · Full text

Rows per page

1–5 of 6